CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.

Autor:	Firestone RS; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., McAvoy D; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Shekarkhand T; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Serrano E; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hamadeh I; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Wang A; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Zhu M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Qin WG; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Patel D; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Tan CR; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Mailankody S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Shah US; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Korde N; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Maclachlan KH; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Landau HJ; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Scordo M; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Shah GL; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lahoud OB; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Giralt S; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Murata K; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hosszu KK; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Chung DJ; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lesokhin AM; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Usmani SZ; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Apr 09; Vol. 8 (7), pp. 1600-1611.
DOI:	10.1182/bloodadvances.2023011225
Abstrakt:	Abstract: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management. (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu